Simon LEIRIS

En résumé

Entreprises

• Antabio - Senior Medicinal Chemist

  Labège 2013 - maintenant Development of small molecule compounds for the treatment of MDR gram-negative bacteria:
  - Design, synthesis and development of novel antibiotics adjuvants to enhance the effectiveness of existing antibiotics
  - Supervision and management of new research projects
  - Development of API's new synthetic routes
  - Bibliographic studies, reports preparations and results presentations

• Pharmaleads - R&D project manager - Chemistry

  2010 - 2013 Design, synthesis and development of metalloproteases inhibitors in the field of endogenous analgesia and antidiarrhea
  - Supervision and management of new research projects: Design, computational visualization (Discovery Studio 3.1) and docking (Gold 5.1) of novel therapeutic targets
  - Multi-step organic synthesis
  - Development of API's new synthetic routes: PL37 (phase II) et PL265 (phase I)
  - Bibliographic studies, reports preparations and results presentations
  - Environment, Health and Safety (EH&S) specialist

• Institut de Chimie des Substances Naturelles (ICSN) - CNRS - Research Engineer - Chemistry

  2009 - 2010 Design and synthesis of Calcium Sensitive Receptor antagonists, derivatives of Calhex231 (treatment against osteoporosis)

• Biodesign Institute - Arizona State University (USA) - Research Associate - Chemistry

  2007 - 2009 - Synthesis of natural Topopyrones and analogues as potential Topoisomerase I and II inhibitors (antitumoral agents)
  - Design and synthesis of Verticipyrone analogues as potential mitochondria complex I inhibitors (antiparasitic agents)
  

Formations

Réseau

• Alexandre SIMON

• Anne FREY-LEJEUNE

• Camille DESTOMBES

• Frédérique BROSSILLON

• Guillaume BOLLOT

• Herve PORAS

• Nelson GOMES

• Ronan GEALAGEAS

• Stéphanie LOUSTEAU

• Sylvain BOURDOULOUS